Anúncio
Anúncio

VRCA

VRCA logo

Verrica Pharmaceuticals Inc. Common Stock

8.15
USD
Patrocinado
+0.10
+1.27%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

8.03

-0.12
-1.50%

Relatórios de Lucros VRCA

Rácio de surpresa positiva

VRCA separação 16 de 30 últimas estimativas.

53%

Próximo Relatório

Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$4.62M
/
-$0.83
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-67.82%
/
+2666.67%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+1241.72%
/
-65.42%

Verrica Pharmaceuticals Inc. Common Stock earnings per share and revenue

On 14 de nov. de 2025, VRCA reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.68 USD, resulting in a 95.64% surprise. Revenue reached 14.34 milhão, compared to an expected 5.96 milhão, with a 140.70% difference. The market reacted with a -5.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analistas forecast an EPS of -0.83 USD, with revenue projected to reach 4.62 milhão USD, implying an aumentar of 2666.67% EPS, and diminuir of -67.82% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Verrica Pharmaceuticals Inc. Common Stock reported EPS of -$0.03, beating estimates by 95.64%, and revenue of $14.34M, 140.7% above expectations.
The stock price moved down -5.09%, changed from $3.93 before the earnings release to $3.73 the day after.
The next earning report is scheduled for 09 de mar. de 2026.
Based on 7 analistas, Verrica Pharmaceuticals Inc. Common Stock is expected to report EPS of -$0.83 and revenue of $4.62M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio